UEMR Versus HSP in the Treatment of Pedunculated Colorectal Polyps Less Than 10mm in Size

Launched by FUDAN UNIVERSITY · May 21, 2025

Keywords

ClinConnect Summary

This clinical trial is comparing two different methods for treating small growths called pedunculated colorectal polyps, which are less than 10mm in size. The two treatments being studied are underwater endoscopic mucosal resection (UEMR) and hot snare polypectomy (HSP). Both methods aim to safely and effectively remove these polyps during a colonoscopy, which is a procedure that allows doctors to look inside the colon.

To participate in this study, individuals need to be between 35 and 80 years old and have specific types of polyps that meet certain criteria. They must also be able to understand and sign a consent form. However, some people won't be eligible, including those with certain medical conditions, serious diseases, or who are pregnant or breastfeeding. If you join this trial, you can expect to undergo one of the two treatment methods and be monitored for safety and effectiveness. Remember, this study is still in the planning stage, and researchers have not yet started recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged between 35 and 80 years
• • Pedunculated colorectal polyps less than 10mm in size in screening, surveillance or therapeutic colonoscopy
• • 0-Isp or 0-Ip according to Paris classification
• • Patients must sign an informed consent form prior to registration in study
• Exclusion Criteria:
• • Unsuitable for removal by UEMR or HSP
• • Suspected malignancy
• • History of inflammatory bowel disease or colorectal resection
• • Familial adenomatous polyposis or Lynch syndrome
• • Patients taking anticoagulant and antiplatelet agents before the examination
• • Inadequate bowel preparation, defined as a Boston Bowel Preparation Scale score \< 6
• • ASA \>=3
• • Pregnancy or breastfeeding
• • Severe comorbid disease involving the heart, lungs, liver, or kidneys.
• • Concurrent serious conditions, including other active malignancies or severe infectious diseases